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The Bcl-2 family of proteins includes
key regulators of apoptosis (reviewed
in [1,2]), some of which promote cell
death while others prevent it. The
observation that the Bcl-2 family
regulates the release of pro-apoptotic
proteins from mitochondria led to the
concept that members of the family
control cell survival by regulating the
permeability of these organelles [3,4].
Several models explain how this
regulation might be achieved
(reviewed in [5]). One of the models
comes from the intriguing observation
that the tertiary structure of Bcl-2
proteins resembles that of colicins and
diphtheria toxin (DT) [6].
Colicins are toxins made by
bacteria to kill other bacterial strains
(reviewed in [7]). Colicins contain
three domains: the receptor binding,
the translocation and the toxic
domain. Bcl-2 proteins are similar in
structure to the toxic domains, that
kill by making pores in the bacterial
membrane. Perforation dissipates ion
gradients, which leads to the release
of essential metabolites, the influx of
water and cell rupture. This structural
similarity suggested that Bcl-2
proteins might function by making
pores in mitochondrial membranes
(reviewed in [5,8]). Although some
Bcl-2 proteins can indeed form pores
in synthetic lipid membranes, the
model faces substantial challenges
(reviewed in [2]). For example, the
structures of Bax and Bcl-x are
remarkably similar [9], suggesting that
if one of the proteins makes the pores,
the other would likely make them as
well. Yet Bax promotes the release of
pro-apoptotic molecules from
mitochondria, whereas Bcl-x prevents
it. This puzzle has not been made
easier by the difficulty to explain how
Bcl-x or Bcl-2 could prevent release of
proteins from mitochondria by
making pores. These and other
unexplained observations argue that
either the similarity between the
Bcl-2 family and the toxins is a
coincidence, or they share a common
function unrelated to the formation of
pores. I would like to argue in favor of
the second possibility by exploring
the homology of the Bcl-2-like
proteins to diphtheria toxin. 
Diphtheria toxin kills human cells
by a mechanism that is different from
that employed by colicins to kill
bacteria. DT belongs to the AB family
of toxins, which includes bacterial and
plant toxins that are made of two
moieties: A and B (reviewed in [10]).
The A moieties are usually enzymes
that are toxic to the cell. For example,
the A moiety of DT is an ADP-ribosyl
transferase that kills by inactivating an
elongation factor required for protein
synthesis. The B moieties, whose
structures vary, translocate the
A moieties through cell membranes.
The B moiety of DT contains a
receptor binding domain, which binds
a specific cell surface receptor, and a
translocation domain.
How does the A moiety of DT
enter the cytoplasm? Although the
translocation of DT has been
extensively studied, the exact
mechanism remains unclear. The
current view is that binding of DT to
its receptor leads to endocytosis of the
complex. The acidic environment of
the endosome apparently triggers a
conformational change in the
translocation domain. This change
leads to insertion of the B moiety into
the endosomal membrane, and the
concomitant translocation of the A
moiety into the cytoplasm. The
sulfhydryl bond linking the A and
B moieties is reduced in the
cytoplasm, freeing the A moiety.
Importantly, although the
translocation of DT is accompanied
by formation of cation-selective
channels, it is unclear whether the
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channels are required for the
translocation. For example, a modified
DT can translocate the A moiety
without forming any detectable
channels [11]. In contrast to the pores
formed by colicins, channels formed
by DT are not sufficient to kill the
cell. Even models that consider the
channels to be related to toxin
translocation do not argue that the
A moiety simply floats through the
channel but rather suggest that the B
moiety functions as a chaperone that
unfolds the A moiety to pass it
through the channel [10]. Hence, one
can argue that the main function of
the B moiety is to translocate the A
moiety through a cell membrane.
Therefore, I would like to propose
that the structural similarity between
the Bcl-2 proteins and the DT
translocation domain indicates that
the common function of these
proteins is to translocate other
molecules or themselves through
membranes, rather than to form pores.
The hypothesis that Bcl-2-like
proteins are protein translocators
would be pure conjecture if not for
direct evidence that at least some of
these proteins can substitute for the
translocation domain of DT. This
evidence comes from the laboratory of
Richard Youle, who developed an
approach to deliver Bcl-x into cells
[12]. Youle and colleagues replaced
the translocation domain of DT with
Bcl-x, reasoning that Bcl-x may
translocate itself into the cytoplasm if
the homology between the proteins is
functional. Indeed the hybrid protein
which contained Bcl-x fused to the
DT receptor-binding domain not only
efficiently translocated through the
cell membrane but also protected
cells from apoptosis. These
experiments provide direct evidence
that Bcl-x not only structurally
resembles but also functions like the
translocation domain of DT, although
whether the hybrid protein can
translocate proteins other than itself
has not been tested. 
What would the Bcl-2-like
proteins translocate? The intriguing
feature of the toxins is that the A
and B moieties do not necessarily
need to be covalently linked to
complete the translocation. For
example, the B moiety of the
anthrax toxin translocates either of
the toxin’s two A moieties without
forming a covalent bond [10].
Another intriguing observation is
that the B moieties can translocate
proteins unrelated to toxins [13].
Therefore, in principle, any proteins
or other molecules that can bind to
Bcl-2 can be translocated. One
possibility is that the pro-apoptotic
proteins are translocated directly.
Alternatively the release may be a
consequence of the Bcl-2 family
functioning as translocators to create
gradients of proteins, including
gradients of themselves, or of other
molecules.
How would the translocation be
regulated? Toxin translocation is
triggered by the acidic environment,
which changes the toxin
conformation. Perhaps a change in
conformation of the Bcl-2 proteins
may be regulated by other factors, as
was reported for Bax [9]. 
Do the Bcl-2 proteins function
alone or as a part of a protein
complex? An answer to this question
may come from the observation that
when the transmembrane domain of
Bax was replaced with that of Bcl-xL
the chimeric protein failed to
promote apoptosis, even though it
bound to mitochondria [14]. One can
surmise that the transmembrane
domain is more than a membrane
anchor, as is often assumed, but
rather is a specific receptor-binding
domain. This would suggest that the
similarity between Bcl-2 and the DT
B-moiety goes beyond the
translocation domain. The existence
of receptors for Bcl-2-like proteins
may imply that these proteins
function as protein complexes, or in
complexes with other molecules.
In summary, this letter proposes
that the Bcl-2 family, like diphtheria
toxin, function as transmembrane
translocators.
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